Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...

GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market. Preliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 ant ...

Natural killer cells, or NK cells, are elements of the immune system capable of rapidly locating and destroying cancerous or infected cells. Their use in therapy, particularly by equipping them ...

Chen et al. construct a comprehensive immune landscape of lymphatic malformations (LMs) atlas at single-cell resolution, uncovering pro-inflammatory responses and immune dysfunction characteristic.